Compare Inovio Pharmaceuticals Inc (INO) vs Kaltura Inc (KLTR) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

Kaltura (KLTR) trades at $1.43, up 2.88% on the day, with a bullish technical signal. The company shows improving fundamentals, with revenue stabilizing around $180M and net losses narrowing significantly from -$68M in 2022 to -$12M in 2025. Recent quarters have consistently beaten EPS expectations, and the company has garnered multiple industry awards, highlighting its leadership in agentic digital experience platforms.

The outlook is cautiously optimistic, with a path to profitability emerging, but risks remain from high debt levels and negative ROE. Analyst sentiment is mixed but leans positive, with 44% recommending Buy. The stock's valuation appears stretched on a P/B basis, requiring sustained execution for further upside.